← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies
inebilizumab
L04AG10
Forms & Strengths
- Intravenous infusion: 300 mg/15 mL (20 mg/mL) single-dose vial
Adult Dosing
- Initial: 300 mg intravenous infusion, followed 2 weeks later by a second 300 mg intravenous infusion
- Maintenance: 300 mg intravenous infusion once every 6 months, starting 6 months after the initial dose
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Indications
- Treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) IgG-seropositive adult patients
Mechanism of Action
- Humanized monoclonal antibody directed against CD19, a cell surface antigen expressed on B cells
- Binds to CD19 and depletes CD19-expressing B cells, including plasmablasts and plasma cells that produce AQP4 autoantibodies
Contraindications
- History of a life-threatening infusion reaction to inebilizumab
- Active hepatitis B infection
- Active or persistent severe infections until resolution
Adverse Reactions
- Urinary tract infection
- Arthralgia
- Infusion reactions (headache, nausea, pyrexia, myalgia)
- Back pain
- Elevated hepatic transaminases
- Hypogammaglobulinemia
Drug Interactions
- Live-attenuated or live vaccines (administration not recommended concurrently or prior to discontinuation and B-cell recovery)
- Immunosuppressive therapies (may increase the risk of immunosuppression when used in combination)
Curated Content: Needs Vetting Before Put to Clinical Use